Adaptive Biotechnologies posts Q3 profitability, raises full-year MRD revenue guidance
The company reported adjusted EBITDA of $14.3 million for the quarter and lifted its 2026 MRD revenue outlook to $276 million to $286 million, citing new myeloma testing guidelines.
SEC filing